3 New Cancer Immunotherapies Waiting To Blast Off in 2018
December 27, 2017
Immuno-oncology (I/O) therapeutics have revolutionized certain types of cancer treatments. They are, in many ways, as close to miracle cures as we’ve seen in decades. Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda together are expected to create $8 billion in revenue this year. Keith Speights, with The Motley Fool, looks at three companies whose I/O efforts are particularly promising in 2018.
1. Incyte’s epacadostat
This compound is an IDO inhibitor. Indoleamine 2,3-dioxygenase (IDO) is a protein generated by some cancer cells that shuts down T cells. Merck and Incyte are conducting the Echo-301 clinical trial to evaluate a combination therapy of Keytruda and epacadostat in melanoma, with results expected in the first half of 2018.
Speights notes, “Epacadostat’s potential is so great that several major drugmakers have teamed up with Incyte to test the drug in combination with their own immunotherapies. Bristol-Myers Squibb and Incyte are evaluating a combination of Opdivo and epacadostat in late-stage studies targeting no-small cell lung cancer (NSCLC) and head and neck cancer. AstraZeneca and Incyte are also working together in testing a combination of Imfinzi and epacadostat in treating NSCLC.”